Association of HIV status with local immune response to anal squamous cell carcinoma: Implications for immunotherapy

JAMA Oncology

Volumn 3, Issue 7, 2017, Pages 974-978

  Yanik, Elizabeth L ^a   Kaunitz, Genevieve J ^b   Cottrell, Tricia R ^b   Succaria, Farah ^b   McMiller, Tracee L ^b   Ascierto, Maria L ^b   Esandrio, Jessica ^b   Xu, Haiying ^b   Ogurtsova, Aleksandra ^b   Cornish, Toby ^c   Lipson, Evan J ^b   Topalian, Suzanne L ^b   Engels, Eric A ^a   Taube, Janis M ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LYMPHOCYTE ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN LAG 3; UNCLASSIFIED DRUG; CD223 ANTIGEN; CD274 PROTEIN, HUMAN; CD3 ANTIGEN; CD4 ANTIGEN; CD68 ANTIGEN, HUMAN; CD8 ANTIGEN; DIFFERENTIATION ANTIGEN; INTERLEUKIN 18; LEUKOCYTE ANTIGEN;

ADULT; ANAL SQUAMOUS CELL CARCINOMA; ANUS CARCINOMA; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DENSITY; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; MALE; SQUAMOUS CELL CARCINOMA; TUMOR CELL; TUMOR MICROENVIRONMENT; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CASE CONTROL STUDY; COMPLICATION; IMMUNOLOGY; IMMUNOTHERAPY; MIDDLE AGED; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; ANTIGENS, CD; ANTIGENS, CD274; ANTIGENS, CD3; ANTIGENS, CD4; ANTIGENS, CD8; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; INTERLEUKIN-18; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 85019266093     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2017.0115     Document Type: Article

References (15)

1. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16(5):275-287.
2. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370 (9581):59-67.
3. Nghiem PT, Bhatia S, Lipson EJ, et al. PD-1 Blockade with Pembrolizumab in advanced merkel-cell carcinoma. N Engl J Med. 2016;374(26): 2542-2552.
4. Seiwert TY, Haddad RI, Gupta S, et al. Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): preliminary results from KEYNOTE-012 expansion cohort [ASCO abstract LBA6008]. J Clin Oncol. 2015;33(suppl).
5. Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4(127):127ra37.
6. Fury M, Ou SI, Balmanoukian AS, et al. Clinical activity and safety of MEDI4736, an anti-PD-L1 antibody, in head and neck cancer [ESMO abstract 5656]. Ann Oncol. 2014;25(suppl):iv340-iv356.
7. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373 (17):1627-1639.
8. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373 (2):123-135.
9. Massard C, Gordon MS, Sharma S, et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol. 2016;34(26): 3119-3125.
10. Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016;17(6):717-726.
11. Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis. 2002;35 (9):1127-1134.
12. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol. 2006;90:1-50.
13. Morris VK, Ciombor KK, Salem ME, et al. A multi-institutional eETCTN phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal (SCCA) [ASCO abstract 3503]. J Clin Oncol. 2016;34(suppl).
14. Torre D, Pugliese A. Interleukin-18: a proinflammatory cytokine in HIV-1 infection. Curr HIV Res. 2006;4(4):423-430.
15. Iannello A, Samarani S, Debbeche O, et al. Role of interleukin-18 in the development and pathogenesis of AIDS. AIDS Rev. 2009;11(3):115-125.